Ho Chi Minh City University of Medicine and Pharmacy has just completed a research project “Evaluating the safety and effectiveness of Vstent – Sirolimus drug-eluting coronary stent (made in Vietnam) in coronary intervention”. The chair of implementing this scientific research is Prof. TS.BS Truong Quang Binh and the co-chair is Assoc. Prof. TS.BS Ho Thuong Dung.
The Sirolimus drug-eluting coronary stent system is currently used to treat the occlusion/narrowing of the arteries caused by atherosclerotic plaques, mainly formed from cholesterol deposits on the vessel walls, and at the same time significantly reduce the complications of restenosis by release of anti-proliferative drugs.
Statistics on research results using Vstent products, reaching the rate of 100% in terms of equipment, 99.3% in terms of procedures (Photo provided by the research team)
Prof. Dr. Doctor Truong Quang Binh, Deputy Director of Ho Chi Minh City University of Medicine and Pharmacy Hospital, Director of Cardiovascular Center of Ho Chi Minh City University of Medicine and Pharmacy Hospital, Senior Lecturer at University of Medicine and Pharmacy of Ho Chi Minh City, said from February 2019 , Vstent – the first drug-coated coronary stent manufactured in Vietnam – has been granted a circulation license by the Ministry of Health.
Despite initial success and obvious effectiveness in treatment, data collected for evaluation is limited (only over 40 patients and 6 months of follow-up at Cho Ray Hospital). Therefore, a study is needed to help the health sector in Ho Chi Minh City in particular and the whole country in general have more objective data, thereby making evaluations of the safety and effectiveness of Vstent products. in coronary intervention.
Prof. Dr. Dr. Truong Quang Binh and his colleagues conducted an evaluation study on 150 patients (at 5 hospitals including University Hospital of Medicine and Pharmacy in Ho Chi Minh City, Thong Nhat Hospital, Khanh Hoa Provincial General Hospital, and Hospital. Kien Giang Provincial General Hospital, and Ba Ria Hospital) performed a percutaneous coronary revascularization procedure with Vstent, then monitored until the patient’s condition stabilized. Post-discharge patients were scheduled to visit every 30 days, and up to the 12th month from the time of study participation.
Reported to the pre-acceptance advisory council (established by the Department of Science and Technology of Ho Chi Minh City), the representative of the research team said to evaluate the safety and effectiveness of Vstent products before and after percutaneous coronary intervention. record 100% success rate on equipment; 99.3% of procedures and no complications; The rate of restenosis is only 3.5%, equivalent to many types of stents currently used in the world.
A representative of USM Healthcare company (in the High-Tech Park of Thu Duc City, Ho Chi Minh City) – where Vstent products are manufactured, said that the average price of Vstent products is under VND 30 million/piece, 30% lower than that of stents. Therefore, the product is expected to help many domestic patients have the opportunity to access treatment.